MD Anderson Cancer Center researchers used both clinical samples and laboratory models to demonstrate that higher levels of a specific mucin-degrading bacteria are associated with a higher incidence of febrile neutropenia and that treatment with antibiotics helped restore those levels to normal.
BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.
A study led by researchers from NYU Grossman School of Medicine and UC San Diego Moores Cancer Center linked the extent of genomic loss of region 9p24 on chromosome 9 in the cancer cells of patients with HPV-negative head and neck squamous cell carcinoma to survival duration after checkpoint inhibitor therapy.
A new study led by a University of Cincinnati researcher provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A large study by researchers at the American Cancer Society demonstrated that adult cancer survivors, particularly those diagnosed within five years and/or those who have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to older adults without cancer.
Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
Researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.
Researchers at VCU Massey Cancer Center published study findings that establish rationale for the use of a class of drugs known as MDA-9 inhibitors as a potential treatment option for aggressive liver cancer.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
